Cambridge Investment Research Advisors’s Humana HUM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.3M Sell
3,267
-100
-3% -$28.5K ﹤0.01% 1909
2026
Q1
$584K Sell
3,367
-754
-18% -$155K ﹤0.01% 2657
2025
Q4
$1.05M Sell
4,121
-904
-18% -$237K ﹤0.01% 2051
2025
Q3
$1.31M Buy
5,025
+440
+10% +$116K ﹤0.01% 1845
2025
Q2
$1.12M Sell
4,585
-23
-0.5% -$5.73K ﹤0.01% 1858
2025
Q1
$1.22M Buy
4,608
+145
+3% +$39.2K ﹤0.01% 1701
2024
Q4
$1.13M Sell
4,463
-602
-12% -$161K ﹤0.01% 1766
2024
Q3
$1.6M Sell
5,065
-796
-14% -$283K 0.01% 1522
2024
Q2
$2.19M Buy
5,861
+1,017
+21% +$343K 0.01% 1224
2024
Q1
$1.68M Sell
4,844
-5,479
-53% -$2.08M 0.01% 1382
2023
Q4
$4.73M Buy
10,323
+1,127
+12% +$555K 0.02% 732
2023
Q3
$4.47M Buy
9,196
+2,124
+30% +$998K 0.02% 711
2023
Q2
$3.16M Buy
7,072
+1,577
+29% +$794K 0.01% 888
2023
Q1
$2.67M Sell
5,495
-1,172
-18% -$579K 0.01% 975
2022
Q4
$3.42M Buy
6,667
+1,575
+31% +$828K 0.02% 791
2022
Q3
$2.47M Buy
5,092
+1,005
+25% +$489K 0.01% 920
2022
Q2
$1.91M Sell
4,087
-157
-4% -$69.9K 0.01% 1070
2022
Q1
$1.85M Sell
4,244
-1,408
-25% -$589K 0.01% 1183
2021
Q4
$2.62M Sell
5,652
-1,727
-23% -$764K 0.01% 993
2021
Q3
$2.87M Sell
7,379
-296
-4% -$126K 0.01% 891
2021
Q2
$3.4M Buy
7,675
+4,032
+111% +$1.76M 0.02% 823
2021
Q1
$1.53M Buy
3,643
+251
+7% +$100K 0.01% 1164
2020
Q4
$1.39M Sell
3,392
-306
-8% -$127K 0.01% 1120
2020
Q3
$1.53M Sell
3,698
-535
-13% -$215K 0.01% 945
2020
Q2
$1.64M Buy
4,233
+614
+17% +$230K 0.01% 859
2020
Q1
$1.14M Sell
3,619
-548
-13% -$185K 0.01% 910
2019
Q4
$1.53M Buy
4,167
+104
+3% +$33K 0.01% 928
2019
Q3
$1.04M Sell
4,063
-206
-5% -$57.8K 0.01% 1047
2019
Q2
$1.13M Sell
4,269
-11,108
-72% -$2.82M 0.01% 965
2019
Q1
$4.09M Sell
15,377
-559
-4% -$161K 0.04% 437
2018
Q4
$4.57M Buy
15,936
+570
+4% +$181K 0.05% 355
2018
Q3
$5.2M Sell
15,366
-63
-0.4% -$20.5K 0.05% 356
2018
Q2
$4.59M Buy
15,429
+18
+0.1% +$5.27K 0.05% 364
2018
Q1
$4.14M Buy
15,411
+12,039
+357% +$3.26M 0.05% 370
2017
Q4
$836K Buy
3,372
+534
+19% +$132K 0.01% 994
2017
Q3
$691K Buy
2,838
+743
+35% +$182K 0.01% 1033
2017
Q2
$504K Buy
2,095
+92
+5% +$20.8K 0.01% 1196
2017
Q1
$413K Sell
2,003
-2,473
-55% -$511K 0.01% 1171
2016
Q4
$913K Sell
4,476
-132
-3% -$25.2K 0.02% 726
2016
Q3
$815K Sell
4,608
-910
-16% -$158K 0.02% 779
2016
Q2
$993K Buy
5,518
+143
+3% +$25.4K 0.02% 599
2016
Q1
$983K Buy
5,375
+1,447
+37% +$251K 0.02% 582
2015
Q4
$701K Buy
3,928
+1,000
+34% +$175K 0.02% 696
2015
Q3
$524K Sell
2,928
-135
-4% -$25K 0.02% 738
2015
Q2
$586K Buy
3,063
+2
+0.1% +$371 0.02% 733
2015
Q1
$545K Buy
3,061
+51
+2% +$8.07K 0.02% 752
2014
Q4
$432K Sell
3,010
-1,164
-28% -$159K 0.01% 849
2014
Q3
$544K Buy
4,174
+239
+6% +$30.4K 0.02% 790
2014
Q2
$503K Sell
3,935
-230
-6% -$27.2K 0.02% 754
2014
Q1
$470K Buy
4,165
+781
+23% +$81.4K 0.02% 740
2013
Q4
$349K Buy
+3,384
New +$332K 0.01% 810

Other funds holding HUM

Cambridge Investment Research Advisors's HUM Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Humana (HUM) stake by 3% in Q2 2026, selling an estimated $28.5K and leaving 3,267 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1909.

Cambridge Investment Research Advisors first reported a position in HUM in Q4 2013 and has held it in 51 quarters since. The position peaked at $5.2M in Q3 2018. 241 funds tracked by Wall St. Rank hold HUM as of Q2 2026.

  • Cambridge Investment Research Advisors held 3,267 shares of Humana worth $1.3M as of Q2 2026.
  • Cambridge Investment Research Advisors sold 100 Humana shares in Q2 2026, an estimated $28.5K.
  • Humana made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1909 holding.
  • Cambridge Investment Research Advisors first reported a position in Humana in Q4 2013 and has held it in 51 quarters since.
  • Cambridge Investment Research Advisors's Humana position peaked at $5.2M in Q3 2018.
  • 241 funds tracked by Wall St. Rank held Humana as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.